Todos Medical Ltd.

Equities

TOMDF

IL0011392375

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:38:22 12/07/2024 am IST			5-day change	1st Jan Change
0.00001 ^USD	+900.00%		0.00%	-95.00%

2023	Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	CI
2023	Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	CI

Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

January 12, 2022 at 08:26 pm IST

Todos Medical Ltd. announced that topline results from the Tollovir™ Phase 2 clinical trial for the treatment of hospitalized COVID-19 patients will be announced the morning of January 27th, 2022, with a conference call follow-up that will occur after market close. The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial.

Latest news about Todos Medical Ltd.

Todos Announces Notice of Allowance from Uspto for Patent Application Covering Use of Compositions in Tollovid?? and Tollovir?? Ingredients	30/23/30	CI
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics	14/23/14	CI
Todos Medical Ltd. Enters into Exclusive Worldwide Automated Retail Supply Agreement with Smart Automated Retail Network	16/22/16	CI
Todos Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Todos Medical Terminates Tollovid Products License & Distribution Agreement with T-Cell Protect Hellas S.A	10/22/10	CI
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for Monkeypox PCR Test to US FDA	14/22/14	CI
Todos Medical Announces USPTO Trademark Notice of Allowance for 3Cl Protease Biomarker Diagnostics Tollotest™	27/22/27	CI
Todos Medical Ltd. Enters into $50 Million Contract to Supply Tollovid(TM) and CBD Products to Retail Distributor Company Nerd Hemp	23/22/23	CI
Todos Medical Initiates Validation Plan for PCR-Based Polio Testing at CLIA/Cap Laboratory Provista Diagnostics	14/22/14	CI
Todos Medical, Ltd. Signs to Agreement with Its 3CL Protease Biology Theranostics Partner NLC Pharma, Ltd	12/22/12	CI
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production	31/22/31	CI
Todos Medical Announces Saliva-Only Monkeypox Testing At Clia/Cap Clinical Lab Provista Diagnostics	26/22/26	CI
Todos Medical, Ltd. Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series	25/22/25	CI
Todos Medical, Ltd Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women	23/22/23	CI
Todos Medical Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	23/22/23	CI
Todos Medical Ltd. Completes Trial Design for Tollovid™ Long Covid Clinical Study in Adults	11/22/11	CI
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels At CLIA/CAP Lab Provista Diagnostics	10/22/10	CI
Todos Medical, Ltd. Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics	08/22/08	CI
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics	05/22/05	CI
Todos Medical Ltd. Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients	30/22/30	CI
Todos Medical Releases Preliminary Data from Irb-Waived Tollovid® Market Research Study in Acute and Long Covid	23/22/23	CI
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff	22/22/22	CI
Todos Medical Ltd. Completes Validation of 27 Pathogen UTI PCR Panel at its CLIA/CAP Laboratory Provista Diagnostics	13/22/13	CI
Todos Medical, Ltd. Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial Vs. Amyloid PET	03/22/03	CI
Todos Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI

Chart Todos Medical Ltd.

Duration

Period

More charts

Company Profile

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune systemâs response to tumor presence. TBIA analyzes the entire biochemical signatures spectrum including proteins, lipids, nucleic acids and carbohydrates of effected immune cells from peripheral blood, using infrared spectroscopy.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
TODOS MEDICAL LTD.	-95.00%	33.24K
EXACT SCIENCES CORPORATION	-33.56%	9.17B
GUARDANT HEALTH, INC.	+20.26%	4.14B
IOVANCE BIOTHERAPEUTICS, INC.	+9.96%	2.63B
VERACYTE, INC.	-7.18%	1.95B
BGI GENOMICS CO., LTD.	-26.17%	1.85B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+39.24%	1.22B
CAREDX, INC	+51.33%	969M
SEEGENE, INC.	-6.77%	694M
CURIOX BIOSYSTEMS CO., LTD	-18.99%	235M

Bio Diagnostics & Testing